Mena FN

Teva Announces Launch Of The First And Only Generic Version Of Sandostatin® LAR Depot (Octreotide Acetate For Injectable Suspension), In The U.S.

This first-to-market launch showcases Teva's proven strengths in complex generic formulations and enhances Teva's strategic goal of sustaining a generic powerhouse. Octreotide acetate for injectable ...
Monthly Prescribing Reference

Presence of Glass Particles Prompts Recall of Octreotide Acetate Injection

Syringe and Vials To date, the Company has not received any reports of adverse reactions related to this recall. Mylan Institutional LLC, a Viatris Company, has voluntarily recalled 1 lot of ...

Viatris Inc. (VTRS) provides updates on four recent regulatory milestones

Viatris Inc. (NASDAQ:VTRS) is one of the top cheap stocks under $20 to buy now. On December 18, Viatris Inc. (NASDAQ:VTRS) ...
FierceBiotech

Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study

On Track To Initiate Pivotal Trial Of Octreolin TM (An Oral Form Of Octreotide Acetate) In Patients With Acromegaly By Year End 2010 NEW YORK and JERUSALEM, June 14 /PRNewswire/ -- Chiasma, Inc., a ...
Seeking Alpha

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced today the launch of the first and only generic ...
Asia One

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S. GlobeNewswire October 01, 2024 PARSIPPANY, N.J., Oct.